【翰森制药(03692.HK):注射用HS-20093治疗小细胞肺癌上市许可申请获国家药品监督管理局受理】智通财经APP讯,翰森制药(03692.HK)发布公告,于2026年9月2日,集团创新药注射用HS-20093上市许可申请获中国国家药品监督管理局(NMPA)受理,用于治疗既往含铂治疗失败的小细胞肺癌(SCLC)成人患者。注射用HS-20093是一款集团自主研发的B7-H3靶向抗体-药物偶联物(ADC)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.